Tesamorelin & Ipamorelin for Belly Fat & GH Support

Conveniently located to serve the areas of Walnut Creek, Concord, Pleasant Hill, Danville, San Ramon, Lafayette, Orinda and Pleasanton, CA

As the body ages, natural changes in growth hormone signaling, body composition, and metabolic function can make it more difficult to maintain lean muscle and manage abdominal fat—even for people who consistently follow a healthy diet and exercise routine. One area of particular concern is visceral fat, the metabolically active fat stored around the internal organs. Unlike subcutaneous fat, which sits directly beneath the skin, visceral fat is more closely associated with metabolic dysfunction and changes in insulin sensitivity, inflammation, and cardiovascular risk.

Growth hormone (GH) plays an important role in regulating fat metabolism, muscle maintenance, and body composition. GH secretion naturally changes with age, including a reduction in the size and frequency of some GH pulses. For appropriately selected patients, therapies that stimulate the body’s own GH signaling may offer another tool for addressing changes in body composition.

Tesamorelin and ipamorelin are peptide therapies that stimulate endogenous growth hormone release through different signaling pathways. Rather than directly replacing growth hormone, they are designed to encourage the pituitary gland to release GH. Tesamorelin has the strongest clinical evidence for reducing visceral adipose tissue and is FDA-approved specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Dr. Amit Rajguru is board-certified in Internal Medicine and fellowship-trained in Anti-Aging, Regenerative, and Functional Medicine (A4M). At Evolved Medical, we use tesamorelin and ipamorelin as part of a structured, lab-monitored protocol for patients seeking measurable improvements in body composition and metabolic health.

To find out whether this therapy is appropriate for your goals, contact us online or call our office at (925) 433-8444.

About Tesamorelin and Ipamorelin

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to increase endogenous growth hormone secretion, which in turn increases levels of insulin-like growth factor-1 (IGF-1).

Tesamorelin is unique among body-composition therapies because it has been specifically studied for its effects on visceral adipose tissue. In randomized clinical trials involving adults with HIV-associated abdominal fat accumulation, tesamorelin produced meaningful reductions in visceral fat compared with placebo. Research has also demonstrated improvements in measures such as waist circumference and, in some studies, liver fat and lean body mass.

The FDA-approved indication is specifically the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved as a general weight-loss medication, and its FDA labeling notes that it has a weight-neutral effect.

For patients considering tesamorelin outside its FDA-approved indication, the potential benefits and limitations should be discussed carefully with a qualified medical professional.

Ipamorelin

Ipamorelin is a growth hormone-releasing peptide (GHRP) that stimulates GH release through a complementary pathway. Unlike other GHRPs, ipamorelin does so without significantly elevating cortisol or prolactin, which makes it a cleaner option for long-term use. (1) When combined with tesamorelin, the two peptides produce stronger, more sustained GH pulses than either alone — supporting fat reduction, improved recovery, sleep quality, and body composition. (2)

Who This Therapy Is For

This protocol is most appropriate for patients whose body composition is not responding to diet and exercise in the way it should — a pattern consistent with age-related GH decline rather than lifestyle factors alone. Specific presentations that respond well include:

  • Stubborn central/visceral fat accumulation despite appropriate caloric intake and activity
  • Metabolic syndrome or insulin resistance with an abdominal fat component
  • Poor sleep quality and slow recovery from physical activity
  • Patients seeking GH support without exogenous hormone replacement
  • HIV-associated lipodystrophy

Candidates must be in good general health, have realistic expectations, and be willing to commit to a structured protocol including regular follow-up and lab monitoring.

Why Consider Growth Hormone Therapies?

Peptide therapy is not solely about reducing the number you see on the scale or fitting into smaller pants. In many cases, the focus is on improving body composition—particularly reducing excess visceral fat while developing lean tissue and boosting metabolic health.

Clinical research on tesamorelin has demonstrated reductions in visceral adipose tissue in appropriately selected populations. In one randomized trial, six months of tesamorelin treatment significantly reduced visceral fat compared with placebo. A larger clinical study also found reductions in visceral fat, trunk fat, and waist circumference.

These findings are important because visceral fat and total body weight are not the same thing. A patient may experience meaningful changes in abdominal composition without dramatic changes on the scale. Fat is less dense than muscle, so true body weight may remain the same or unchanged. However, with growth hormone support and belly fat reduction, this weight now comes from lean, strong tissue rather than calorie reserves.

That distinction is one reason treatment should be evaluated using multiple measures, including waist circumference, body composition, laboratory markers, symptoms, and overall health—not weight alone.

What to Expect

Consultation

Every protocol starts with a thorough evaluation — medical history, lifestyle factors, and baseline labs — before any treatment is recommended. From there, we design a personalized plan that may include tesamorelin, ipamorelin, or both, with clear dosing schedules and defined outcome targets. All questions about how the therapy works, what to expect, and how it fits into your broader health plan are addressed before you start.

Contact us online or call our office at (925) 433-8444 to schedule your consultation.

Procedure

Tesamorelin and ipamorelin are self-administered via small subcutaneous injections, five days per week. Standard dosing options are:

  • Standard: 20 units, five days per week
  • High-dose: 40 units, five days per week (transitioned to after one month if clinically appropriate)

Injections are typically taken on an empty stomach, either first thing in the morning or at bedtime. Our team will walk you through proper injection technique and storage before you begin at-home administration. Treatment plans are structured as subscription programs — including vials, labs, and follow-up visits — to ensure consistency and ongoing monitoring.

Follow-Up

Progress is tracked through regular follow-up visits and lab testing. Dosing is adjusted as needed based on clinical response.

Recovery

Tesamorelin and ipamorelin for belly fat and growth hormone support do not require any downtime. Patients resume normal activity immediately after each injection. Minor injection site irritation is common and typically resolves quickly.

Results

Initial changes — improved sleep, better energy, faster recovery — are typically reported within the first few weeks. Visible reduction in abdominal girth generally becomes apparent between three and six weeks as visceral fat reduction begins to affect waist circumference. More significant improvements in lean mass, body composition, and metabolic markers typically develop over three months of consistent therapy.

Results are most pronounced when peptide therapy is paired with appropriate nutrition, consistent exercise, and routine follow-up. Individual outcomes vary.

Cost

Single vial $165

Standard subscription (3 months) $375 — includes 6 vials, labs, and follow-up visits

High-dose subscription (3 months) $525 — includes 12 vials, labs, and follow-up visits

A detailed cost breakdown is provided during your consultation based on your specific protocol. Contact us online or call (925) 433-8444 to get started.

FAQ

What is tesamorelin?

Tesamorelin is a synthetic GHRH analog that stimulates natural growth hormone release from the pituitary. It is FDA-approved for visceral fat reduction in HIV-associated lipodystrophy and is used off-label in a broader metabolic context.

What is ipamorelin?

pamorelin is a GHRP that stimulates GH release without significantly elevating cortisol or prolactin — making it well-suited for ongoing use alongside tesamorelin.

How do these peptides reduce belly fat?

Tesamorelin targets visceral fat directly at the gene expression level. Combined with ipamorelin, the resulting increase in GH pulsatility improves fat mobilization and metabolic function over time.

How is the therapy administered?

Subcutaneous self-injection, five days per week. Our team provides full instruction on technique and storage before you administer at home.

When do results appear?

Sleep, energy, and recovery improvements are typically reported within the first few weeks. Visible changes in abdominal fat generally appear between weeks three and six, with more significant body composition changes developing over three months.

Can this be combined with hormone therapy or GLP-1 medications?

Yes. Tesamorelin and ipamorelin target GH secretion pathways that are distinct from sex hormone optimization and GLP-1 receptor signaling. These therapies generally complement rather than interfere with one another, though protocols are always reviewed individually.

The information on this page is for educational purposes only and is not intended as medical advice. Tesamorelin is FDA-approved specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy and is not approved for general weight loss or belly fat reduction in otherwise healthy adults. Ipamorelin is not FDA-approved for human use and is considered a research compound. Individual results may vary. Always consult a licensed healthcare professional before beginning any peptide therapy or growth hormone-related treatment.

References

  1. Adrian S, Scherzinger A, Sanyal A, et al. THE GROWTH HORMONE RELEASING HORMONE ANALOGUE, TESAMORELIN, DECREASES MUSCLE FAT AND INCREASES MUSCLE AREA IN ADULTS WITH HIV. The Journal of Frailty & Aging. Published online 2018:1-6. doi:10.14283/jfa.2018.45
  2. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(S2):S149–S14S159. doi:10.21037/tau.2019.11.30